Trazodone on OSA Endotypes - Trial NCT06286189
Access comprehensive clinical trial information for NCT06286189 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Brigham and Women's Hospital and is currently Recruiting. The study focuses on Obstructive Sleep Apnea. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Brigham and Women's Hospital
Timeline & Enrollment
Phase 1/2
Jan 01, 2024
Jun 01, 2025
Primary Outcome
Effect of trazodone on arousal threshold (%eupnea)
Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment
 options are limited. Some OSA patients with low arousal threshold wake up prematurely during
 an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle
 recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this
 protocol the investigators will test the effect of trazodone administered before sleep on OSA
 traits and OSA severity during sleep.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06286189
Non-Device Trial